Plain-English translation of NCT05906433 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing Kenalog, a steroid medication injected directly into the knee to reduce arthritis pain. The researchers want to know whether adding different amounts of numbing medicine (or no numbing medicine at all) to the injection changes how much pain you feel during the procedure and how long the pain relief lasts afterward.
Doctors already know that steroid injections help ease knee arthritis pain, but they're not sure what the best way to give the injection is. This medication works well, but researchers want to figure out if the amount of numbing medicine used alongside it matters for comfort and effectiveness.
You likely qualify if…
You likely don't qualify if…
You will receive one injection of the steroid medication into your knee, and you'll be randomly assigned to receive it with either no numbing medicine, a standard amount of numbing medicine, or a smaller amount of numbing medicine. The researchers will ask you to rate your pain during the injection and at several time points afterward to see how much pain you felt and how long the relief lasts.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
Foundation for Orthopaedic Research and Education
Collaborators
Florida Orthopaedic Institute
Enrollment target
~75 participants
Started
June 2023
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anne Meredith Baldy, CCRC
Foundation for Orthopaedic Research and Education
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.